Douglass Winthrop Advisors LLC Buys 9,022 Shares of AbbVie Inc. $ABBV

Key Points

• Douglass Winthrop Advisors LLC increased its stake in AbbVie by 21.5%, buying 9,022 shares to hold 50,968 shares valued at about $11.80 million at quarter-end.
• AbbVie beat Q results (EPS $2.71 vs $2.65 est.; revenue $16.62B, +10% YoY), issued FY2026 guidance of 14.370–14.570 EPS, and declared a quarterly dividend of $1.73 (annualized $6.92, ~3.0% yield; ex-dividend Apr 15, payable May 15).
• The stock carries a consensus rating of "Moderate Buy" with an average target of $253.15, though recent insider selling and competitive pressure (Skyrizi trial loss) introduce near-term sentiment risk despite some analyst upgrades.

Douglass Winthrop Advisors LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 21.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,968 shares of the company's stock after buying an additional 9,022 shares during the quarter. Douglass Winthrop Advisors LLC's holdings in AbbVie were worth $11,801,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Caitlin John LLC bought a new stake in AbbVie during the 3rd quarter worth approximately $33,000. Redmont Wealth Advisors LLC bought a new stake in AbbVie during the 3rd quarter worth approximately $41,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie in the 2nd quarter valued at $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $227.58 on Thursday. The firm has a market capitalization of $402.40 billion, a PE ratio of 96.43, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a fifty day moving average of $224.58 and a 200 day moving average of $224.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the business posted $2.16 earnings per share. The company's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie's payout ratio is presently 293.22%.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. HSBC upgraded shares of AbbVie from a "hold" rating to a "buy" rating and boosted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, January 21st. Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a research note on Monday. Finally, Barclays initiated coverage on AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Elahere market opportunity highlighted — A market research report reiterates growing epidemiology and adoption tailwinds for Elahere (mirvetuximab soravtansine), supporting long-term revenue upside for AbbVie’s oncology franchise. Elahere Market Report
• Positive Sentiment: Obesity program visibility — Coverage noting AbbVie (with partner Regeneron) showcased obesity data, which keeps investor focus on higher-growth cardiometabolic opportunities beyond legacy immunology products. BiopharmaDive article
• Neutral Sentiment: Phase I ABBV‑295 topline reported — AbbVie released topline data from its ABBV‑295 Phase I study; investors will watch detailed readouts and next‑step decisions for any meaningful share‑price impact. Topline ABBV‑295 report
• Neutral Sentiment: Leerink conference presentation — Management provided updates at the Leerink Global Healthcare Conference; these transcripts supply incremental detail but no blockbuster surprises were flagged in headlines. Leerink transcript
• Neutral Sentiment: Citi keeps Hold rating — Analyst Geoff Meacham maintained a Hold and $230 PT, signaling limited near‑term upside in street estimates despite pipeline promise. TipRanks/Citi note
• Neutral Sentiment: Sector tailwinds — Commentators (Josh Brown, others) argue large‑cap biotech is resilient to disruption, which can buoy AbbVie as a defensive growth biotech holding. Josh Brown/sector view
• Negative Sentiment: Skyrizi lost in psoriatic arthritis trial — UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a head‑to‑head psoriatic arthritis study, raising competitive risk for a core immunology franchise and putting pressure on future Skyrizi sales growth. Seeking Alpha: Skyrizi vs Bimzelx
• Negative Sentiment: Coverage: UCB victory emphasized — Trade press picked up the Bimzelx win, amplifying market concern about competitive erosion in AbbVie’s immunology portfolio. FiercePharma coverage
• Negative Sentiment: Insider selling headline — Reports of insider selling (small headline move) can weigh on sentiment and were cited as a driver of a near‑term pullback. Insider selling report
• Negative Sentiment: CEO pay increase draws attention — A sizeable pay bump for CEO Robert Michael may raise governance concerns among some investors. CEO pay article

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.